Portfolio, Platform, Partnership

Therapeutic Assets

(Scale, Quality, Speed)

>1000 Ab Building Blocks

  • Human/humanized

  • mAb, VHH, FAB w/CLC

  • For ADC, TCE, Multi-specifics

>100 Therapeutic Targets

  • Oncology, I&I, Metabolism, CNS

  • Clinically Validated and Emerging

  • Modality Agnostic

>10 Differentiated Programs

  • FIC or BIC

  • DC, IND, Ph1/2 (POC) Stage

  • Long-Acting Peptide, CNS AAV, AOC

Innovative Platforms

(Proprietary, Versatile, Broad)